Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Boston Scientific (NY: BSX )

68.41 +0.97 (+1.43%)
Streaming Delayed Price Updated: 1:51 PM EDT, Apr 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Boston Scientific

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA
BofA Securities' upgrades Integer, highlighting the growth potential of pulsed field ablation (PFA) in atrial fibrillation treatment. With projections of PFA sales skyrocketing from $100-200 million in... 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Unveiling 13 Analyst Insights On Boston Scientific
Via Benzinga
5 Things to Know in Investing This Week
The Shockwave Issue 
Via Benzinga
Looking Into Boston Scientific's Recent Short Interest
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $8,100 Today
Via Benzinga
NYSE:BSX may be ready to breakout.
Will BOSTON SCIENTIFIC CORP breakout? 
Via Chartmill
$1000 Invested In This Stock 10 Years Ago Would Be Worth $5,200 Today
Via Benzinga
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Johnson & Johnson reportedly in talks to acquire Shockwave Medical. Potential acquisition aligns with J&J's interest in expanding into cardiovascular devices. Piper Sandler considers J&J a potential... 
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A look at five stocks that are seeing increased attention from investors and Benzinga readers. The list includes several large cap stocks for the week. 
Via Benzinga
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
Exposures Death
Tandem Diabetes Care Stock Belongs On Your Watchlist As RS Rating Jump Higher
On Monday, Tandem Diabetes Care stock received an upgrade to its Relative Strength (RS) Rating, from 68 to 78. 
Via Investor's Business Daily
17 Analysts Have This To Say About Boston Scientific
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today
Via Benzinga
$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Boston Scientific Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks. 
Via Benzinga
Citadel Is The Most Successful Hedge Fund In History: Here Are Its Top Investment Picks
Via Benzinga
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Key Takeaways From Boston Scientific Analyst Ratings
Via Benzinga
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 10 Years
Via Benzinga
Stryker Stock Sees Relative Strength Rating Jump To 84
The Relative Strength (RS) Rating for Stryker stock jumped into a new percentile Thursday, with a rise from 76 to 84. 
Via Investor's Business Daily
AT&T To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Biotech And Medtech Portfolio Notes On A Fed Day
The Fed held rates keeping their future options flexible with no expectations for future cuts. The market did not like it and sold off with the Russell 2000 down 2.45% and the NASDAQ down 2.23% 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Nasdaq, S&P 500 Slip Ahead Of Fed Meeting, Regional Banks Sink After NYCB Disappoints: What's Driving Markets Wednesday?
Nasdaq down 1.4%, S&P 500 down 0.9%, Dow up: Volatile day on Wall Street as tech stocks react to disappointing earnings ahead of Fed meeting. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Boston Scientific shares surge in premarket trading following strong Q4 results, beating revenue estimates, amid positive outlook for 2024. 
Via Benzinga
Boston Scientific Surges On Its 'Impressive' First-Quarter Guidance
The company expects sales to grow 7% to 9% organically, above expectations. 
Via Investor's Business Daily
Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts
Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook. 
Via Benzinga
Topics Economy
Exposures Interest Rates
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.